Annovis Bio Earnings Call Transcripts
Fiscal Year 2026
-
Pivotal phase III Alzheimer's trial is fully enrolled, with top-line data expected in March and NDA filing to follow. Additional funding is required to continue operations, with management and insiders planning to participate in the raise. Disease-modifying data in 2028 could unlock significant market opportunities.
Fiscal Year 2025
-
A new orally available Alzheimer's drug targets four toxic proteins, showing both symptomatic and disease-modifying effects in animal and human studies. It demonstrated significant cognitive improvement and broad efficacy across patient subgroups, with an 18-month pivotal trial ongoing.
-
The pivotal phase III Alzheimer's trial is progressing, with full enrollment expected by year-end and key data readouts planned for fall and 2027. Early results show strong efficacy and safety, while Parkinson's studies await funding. Regulatory and investor engagement remains active.